1	Title: Clinical and genomic epidemiology of mcr-9-carrying carbapenem-resistant
2	Enterobacterales isolates in Metropolitan Atlanta, 2012-2017
3	
4	Authors: Ahmed Babiker ^{1,2,} Chris Bower ³⁻⁵ , Joseph D. Lutgring ⁶ , Jessica Howard-
5	Anderson ¹ , Uzma Ansari ⁶ , Gillian McAllister ⁶ , Michelle Adamczyk ^{6,7} , Erin Breaker ⁶ ,
6	Sarah W. Satola ^{1,2,3} , Jesse T. Jacob ^{1,3} , Michael H. Woodworth ^{1,3}
7	
8	Affiliations:
9	
10	1- Division of Infectious Diseases, Department of Medicine, Emory University School of
11	Medicine, Atlanta, GA
12	
13	2- Department of Pathology and Laboratory Medicine, Emory University School of
14	Medicine, Atlanta, GA
15	
16	3- Georgia Emerging Infections Program, Decatur, GA
17	
18	4- Atlanta VA Medical Center, Decatur, GA
19	
20	5- Foundation for Atlanta Veterans Education and Research, Decatur, GA
21	
22	6- Division of Healthcare Quality Promotion, Centers for Disease Control and
23	Prevention, Atlanta, Georgia, USA

- 24
- 25 7- Goldbelt C6, LLC, Chesapeake, Virginia, USA
- 26
- 27 Running title: Genomic epidemiology of mcr-9
- 28
- 29 Key words: healthcare epidemiology, next generation sequencing, CRE, MDR, AMR
- 30
- 31 Corresponding Author: Michael H. Woodworth, Division of Infectious Diseases,
- 32 Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
- 33 Email: michael.holmes.woodworth@emory.edu
- 34
- 35 Alternative Corresponding author: Ahmed Babiker, Division of Infectious Diseases,
- 36 Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
- 37 Email: ahmed.babiker@emory.edu

38 Abstract (Word limit: 250, word count: 250)

39 Colistin is a last-resort antibiotic for multidrug-resistant gram-negative infections. Recently, the ninth allele of the mobile collistin resistance (mcr) gene family, designated 40 41 *mcr-9*, was reported. However, its clinical and public health significance remains 42 unclear. We gueried genomes of carbapenem-resistant Enterobacterales (CRE) for 43 mcr-9 from a convenience sample of clinical isolates collected between 2012-2017 through the Georgia Emerging Infections Program, a population- and laboratory-based 44 45 surveillance program. Isolates underwent phenotypic characterization and whole 46 genome sequencing. Phenotypic characteristics, genomic features, and clinical outcomes of *mcr-9* positive and negative CRE cases were then compared. Among 235 47 sequenced CRE genomes, thirteen (6%) were found to harbor mcr-9, all of which were 48 Enterobacter cloacae complex. The median MIC, rates of heteroresistance and 49 inducible resistance to colistin were similar between mcr-9 positive and negative 50 51 isolates. However, rates of resistance were higher among mcr-9 positive isolates across 52 most antibiotic classes. All cases had significant healthcare exposures. The 90-day mortality was similarly high in both mcr-9 positive (31%) and negative (7%) CRE cases. 53 54 Nucleotide identity and phylogenetic analysis did not reveal geo-temporal clustering. *mcr-9* positive isolates had a significantly higher number of median [range] AMR genes 55 56 (16 [4-22] vs. 6 [2-15]; p < 0.001) compared to mcr-9 negative isolates. Pan genome 57 tests confirmed a significant association of *mcr-9* detection with mobile genetic element and heavy metal resistance genes. Overall, the presence of mcr-9 was not associated 58 59 with significant changes in colistin resistance or clinical outcomes but continued 60 genomic surveillance to monitor for emergence of AMR genes is warranted.

61

62 Introduction

63

With the rise of carbapenem-resistant organisms over the past few decades (1, 2), polymyxins (colistin or polymyxin B) remain last-resort antibiotics for multidrug-resistant gram-negative infections (3). While concerns regarding efficacy and nephrotoxicity (4) have relegated polymixins to the second or third line of the antibiotic armamentarium (5), these agents remain listed as critically important antibiotics by the WHO and are widely used globally.

70

71 In 2015, a colistin-resistance gene localized on a plasmid was designated mobilized 72 colistin resistance-1 (mcr-1) (6). The mcr-1 gene encodes a transferase that adds a phosphoethanolamine residue to cell membrane lipid A, altering the binding site of 73 74 colistin, and consequently leading to colistin resistance (6). Since its initial description in Escherichia coli (6), multiple mcr alleles (mcr-2 to mcr-10.1) have been described (7). 75 The mcr-9 allele was reported in 2019 and is most similar to mcr-3 among previously 76 77 described mcr alleles (8). A recent search of publicly-available sequence databases revealed a wide global distribution of mcr-9-harboring isolates, across six continents 78 and in at least 9 Enterobacterales species (7, 9). However, it is most commonly 79 80 detected among Enterobacter species (9).

81

82 In the US, the initial wave of carbapenem-resistant Enterobacterales (CRE) was

83 predominantly driven by proliferation of KPC-harboring *Klebsiella pneumoniae (1, 10)*;

84	however, as demonstrated in recent reports, a second wave of CRE in the US seems to
85	be driven by the rise of Enterobacter species (1, 11). Genomic analysis indicates this
86	second wave is associated with a high degree of clonal diversity among isolates (12).
87	With the increasing spread of carbapenem-resistant Enterobacter, the dissemination of
88	mcr-9 is highly probable. Despite its global distribution, the impact of mcr-9 on colistin
89	phenotypic susceptibility remain unclear. Moreover, its association with patient clinical
90	outcomes or potential for outbreaks of public health concern is yet to be examined.
91	
92	The Centers for Disease Control and Prevention (CDC)-funded Georgia Emerging
93	Infections Program (GA EIP) performs active, population- and laboratory- based
94	surveillance for CRE isolated from sterile sites or urine in metropolitan Atlanta, GA
95	(population ~4 million). We aimed to estimate the frequency of mcr-9 among CRE cases
96	within the GA EIP catchment area and to compare clinical outcomes and
97	microbiological, genomic, and clinical characteristics of mcr-9 positive and mcr-9
98	negative cases.
99	
100	Results
101	
102	The mcr-9 allele was infrequently detected among GA EIP isolates between 2012-2017
103	
104	Between 2012-2017, the GA EIP identified 1,507 incident CRE cases, 716 (47.5%)
105	were K. pneumoniae; 415 (27.5%), Escherichia coli; 270 (17.9%), Enterobacter cloacae
106	complex; 72 (4.8%), Klebsiella aerogenes (formerly Enterobacter); and 34 (2.3%)

107	Klebsiella oxytoca cases. The overall crude annual CRE incidence across GA EIP
108	increased from 4.6 to 9.6 per 100,000 population from 2012 to 2017. Carbapenem-
109	resistant E. cloacae complex incidence, in particular, increased from 0.37 to 2.3 per
110	100,000 population during the study period. This increase coincided with revision of the
111	CDC case surveillance definition for CRE (13). (Figure 1 A/B, Supplementary Table 1,
112	Supplementary Figure 1).
113	
114	A convenience sample of 384 isolates which met the GA EIP CRE case definition was
115	sent to the CDC for further characterization. Of the 384, 235 (61%) underwent whole
116	genome sequencing (WGS). Among 235 sequenced CRE isolates, thirteen (6%) were
117	found to harbor mcr-9, all of which were E. cloacae complex. All remaining sequenced
118	mcr-9 negative E. cloacae complex (n=14) were included as a comparative group,
119	yielding a total number of 27 E. cloacae complex isolates.
120	
121	Microbiology Characteristics
122	
123	Following collection, isolates underwent reference antimicrobial susceptibility testing by
124	broth microdilution (BMD) at CDC. Of the E. cloacae complex isolates that underwent
125	WGS from 2012-2017, twenty-two isolates (81.7%, 22/27) were confirmed to be
126	carbapenem-resistant. Carbapenem resistance was similar among mcr-9 positive and
127	negative cases (84.6% (11/13) vs. 78.6% (11/14); p=1.00). Fluoroquinolone resistance
128	was significantly higher among mcr-9 positive isolates compared to mcr-9 negative
129	isolates (100% (13/13) vs. 57.1% (8/14); <i>p</i> =0.03). This contributed to a higher proportion

130	of isolates being classified as difficult-to-treat resistance (DTR) (14). Overall, 48.1%
131	(13/27) were classified as harboring DTR (14, 15). with mcr-9 isolates having higher-
132	rates of DTR (61.5% (8/13) vs. 35.7% (5/14) p=0.34). Similarly, rates of aminoglycoside,
133	tetracycline, and trimethoprim-sulfamethoxazole resistance were higher among mcr-9
134	positive isolates compared to mcr-9 negative isolates (Supplementary Table 2).
135	
136	The median [range of concentrations tested] colistin MIC for all E. cloacae complex
137	isolates was 0.5 μ g/mL [≤0.25->8.0]. Proportions of resistance, heteroresistance and
138	inducible resistance were 11.1% (3/27), 48.1% (13/27) and 14.8% (4/27), respectively.
139	There was no significant difference in colistin MIC, heteroresistance or inducible
140	resistance between <i>mcr-9</i> positive and negative isolates (Table 1). Of the three <i>E</i> .
141	cloacae complex isolates which were colistin-resistant by BMD, none were mcr-9
142	positive, although one was positive for mcr-10.1.
143	
144	Clinical characteristics of mcr-9 positive and negative CRE cases.
145	
146	E. cloacae complex isolates were commonly isolated from urine (88.9%, 24/27),
147	followed by blood (7.4%, 2/27) and peritoneal fluid (3.7%, 1/27). All cases had
148	significant healthcare exposures, with 14 cases (51.9%) long term care facility onset, 10
149	(37.0%) healthcare-associated community onset, and 3 (11.1%) hospital onset. Ten
150	patients (37.0%) were hospitalized at time of culture or within 29 days of CRE culture.
151	Among the 10 hospitalized patients, 3 (30.0%) patients were admitted to the ICU within
152	seven days of culture and one patient died during the period of hospitalization (10.0%).
149 150 151	patients (37.0%) were hospitalized at time of culture or within 29 days of CRE cultu Among the 10 hospitalized patients, 3 (30.0%) patients were admitted to the ICU within
152	seven days of culture and one patient died during the period of hospitalization (10.0%).

153	Among hospitalized patients with available follow up data (n=7), 42.8% (3/7) were
154	readmitted within 30 days. Overall unadjusted all-cause 90-day mortality was 18.5%
155	(5/27). No clinical characteristics and outcomes were significantly different, and most
156	were numerically similar among mcr-9 positive and negative cases. 90-day mortality
157	was higher among mcr-9 positive cases (30.7% (4/13) vs. 7.1% (1/14)) compared to
158	mcr-9 negative cases but this was not statistically significant ($p=0.28$).
159	
160	Genomic Analysis
161	
162	To expand the analytic genome set, a comparator cohort of nine publicly-available
163	clinical and environmental carbapenem-resistant E. cloacae complex (three mcr-9
164	positive, six mcr-9 negative) genomes downloaded from National Center for
165	Biotechnology Information (NCBI). Review of associated metadata reveled isolates to
166	have been collected between January 2012 and December 2016 at the National
167	Institutes of Health (NIH) clinical center (Bethesda, MD) (PRJNA430442) (16). These
168	genomes were combined with the 27 GA EIP isolates, resulting in 36 isolate draft
169	genomes included in further comparative genomic analyses.
170	
171	The 13 mcr-9 positive E. cloacae complex isolates were obtained from 10 distinct GA

EIP facilities across the study period (2012-2017). Average nucleotide identity pairwise comparisons revealed three distinct clusters (**Figure 2**). This clustering did appear to be related to geographical location or year of isolation. NIH isolates clustered with GA EIP isolates, and GA EIP isolates did not cluster by facility or year (**Supplementary Figure**

176 2). Their distribution throughout the genome phylogeny suggested that the *mcr-9*177 positive isolates were largely genetically distinct from one another.

178

179 Median [range] AMR gene content (excluding mcr-9) was significantly higher among 180 mcr-9 positive isolates compared to mcr-9 negative isolates (16 [4-22] vs. 6 [2-15]; p 181 <0.001) (Figure 3). Among the three isolates with elevated colistin MICs, no point mutations in *pmrA/pmrB*, a two-component system regulator of lipopolysaccharide (the 182 183 target site of colistin) modifications, were detected. Pan-genome-wide association tests 184 revealed a significant association of *mcr-9* detection with the detection of mobile genetic element (MGE)-associated genes such as repB, parM, hns2; heavy metal resistance 185 186 (HMR) genes such as arsC2, arsB2, fieF2, pcoE2 and merA; and virulence genes such 187 *hipA* (Table 2, Supplementary Table 2, Supplementary Figure 3). Taken together, these comparative genomic analyses across two sites with mcr-9 positive E. cloacae 188 189 complex isolate draft genomes confirmed the colocalization of mcr-9 with plasmid-190 mobilized heavy metal resistance genes but did not provide evidence of a high-identity 191 outbreak cluster in space or time.

192

193 Discussion

194

Among 235 CRE isolates collected through a comprehensive, population-based
surveillance program targeting the most common CRE species, we found a low
prevalence of *mcr-9*, all of which were detected in *Enterobacter cloacae* isolates. Our
phylogenetic analyses revealed a genetically diverse *mcr-9* positive CRE population,

199 suggesting sporadic carriage rather than clonal spread. Using multi-modal phenotypic 200 testing, we were unable to detect impacts of *mcr-9* on colistin susceptibility, however 201 genomic analysis revealed an association with increased AMR. HMR and virulence 202 genes. In addition, our *mcr-9*-containing CRE isolates were exclusively acquired in 203 healthcare settings, with a trend towards increased mortality. Since their initial 204 description, recognition of mcr genes associated with colistin resistance has spread rapidly across the globe (7). Our study of mcr-9-harboring CRE cases provides unique 205 206 insights into the phenotypic and genomic implications of mcr-9, and is one of the first to 207 examine clinical outcomes.

208

Whether mcr-9 confers colistin resistance has been debated (17). The first isolate 209 210 identified to harbor mcr-9 was also susceptible to colistin but the allele was found to confer resistance to colistin when cloned into a colistin-susceptible E. coli and 211 212 expressed under the control of an IPTG-induced promoter. However, this was only at 1, 213 2, and 2.5 mg/L, but not at 5 mg/L of colistin (8). Kieffer et al. later reported that mcr-9 214 expression was inducible in the presence of colistin when located upstream of the two-215 component sensor kinase system *qseBC (17*). This two-component signaling network 216 allows bacteria to sense and respond to their changing environments. In particular, the 217 *qseC* and *qseB* genes encode a histidine kinase sensor (*qseC*) and its cognate partner 218 (gseB). The gseBC system has been shown to interact with pmrA/pmrB, to induce 219 resistance to the colistin(18). However, a study of *mcr-9*-containing isolates from retail 220 meat conducted by the National Antimicrobial Resistance Monitoring System (NARMS), 221 found all 105 isolates (99 S. enterica and 6 E. coli) tested to be susceptible to colistin,

222 including 10 isolates with *gseBC (19*), indicating that the previously demonstrated 223 impact of *qseBC* on *mcr-9* expression and colistin resistance may be dependent on 224 strain backgrounds, as originally demonstrated in E. coli (17). Among clinical CRE 225 isolates, we found the presence of mcr-9 was not associated with frank or inducible 226 colistin resistance. Furthermore, our study is the first to examine the association of mcr-227 9 with heteroresistance. Heteroresistance is a largely unrecognized form of antibiotic 228 resistance where only a subset of cells within a bacterial population are resistant to a 229 given drug (20). These resistant cells can be selected for in the presence of the 230 antibiotic and cause colistin treatment failures in-vivo (21). In a multisite surveillance 231 study of colistin heteroresistance among CRE, Enterobacter spp. and in particular E. 232 *cloacae*, displayed the highest proportion of colistin heteroresistance (22). However, 233 here we found no association between *mcr-9* and colistin heteroresistance.

234

235 Carbapenem-resistant gram-negatives are a public health threat broadly prioritized by 236 public health organizations (23). Given the limited therapeutic options, morbidity and 237 mortality rates are increased disproportionately when compared to infections caused by 238 susceptible bacteria. We observed high 90-day mortality rates, but these were similar to 239 reported CRE mortality rates at other US academic centers (1). However, there was a non-significant trend for higher mortality among mcr-9 positive isolates. This association 240 241 should be further evaluated in larger studies, with adjustment for potentially-confounding variables associated with mortality such as severity of illness, age and comorbidities as 242 243 our small size may underestimate differences in mortality (1). This finding may be 244 related to the increase in phenotypic resistance and AMR gene content associated with

245 *mcr-9*. A similar finding was previously reported describing 1,035 *mcr-9*-containing 246 isolates in which 97% (1003/1035) were classified as MDR (7). This increased AMR 247 gene content, renders isolates not only carbapenem-resistant, but also with DTR, 248 further limiting therapeutic options (14). DTR is a clinically relevant and functional 249 classification of resistance which signifies in vitro resistance to all high-efficacy, low-250 toxicity (or first-line) agents and is associated with worse clinical outcomes when 251 compared to carbapenem-resistant phenotypes (14). Moreover, genome-wide association studies, revealed a difference in key virulence genes such hipA. a 252 253 eukaryote-like serine threonine kinase that inhibits cell growth and induces bacterial 254 persistence (24).

255

256 We found the presence of *mcr-9* to be associated with HMR genes such arsA, merA, conferring arsenic and mercury resistance, respectively. There has been increasing 257 258 evidence for the co-selection of AMR and HMR genes through either co-resistance or 259 cross-resistance (25). Co-resistance occurs when AMR and HMR genes are carried on 260 the same mobile genetic element. IncH12 plasmids, which frequently harbor HMR 261 genes (8), have been found to be the predominant replicon type carrying mcr-9 and frequently demonstrated in our isolates. Hospital wastewater is an increasingly 262 263 recognized reservoir for resistant gram-negative organisms that cause healthcare-264 associated infections (26) and HMR genes may allow for continued persistence in the 265 environment (27). While the community setting is starting to represent an increased 266 source of multidrug-resistant infections (28), the healthcare setting still represents a 267 major risk for MDR acquisition, as was seen among our cohort.

268

269 Our study combines detailed epidemiological, clinical, phenotypic, and genomic data to 270 examine the significance of mcr-9 but has some limitations. Firstly, we could not do a 271 full interrogation of mcr-9-containing plasmids, due to limitations of short read 272 sequencing. However, prior studies have significantly characterized the genomic 273 background of *mcr-9*-containing plasmids (9). Second, our study did not include 274 Salmonella species which are a major reservoir for mcr-9 or other Enterobacterales 275 species such as Citrobacter (7), and our findings may not be generalizable to these 276 species. However, our dataset of 235 includes the most common and significant clinical 277 CRE species (1, 23) and is one of few studies carried out on clinical human isolates 278 (19). Third, while we assessed for presence of the *pmrA/pmrB* regulatory system (29), 279 we did not include assessment of the two-component system *qseBC* (8) or testing conditions (such as the use of cation-adjusted Mueller-Hinton broth) (30) which have 280 281 been shown to influence *mcr-9* expression and the colistin MIC results, respectively. 282 Fourth, while our overall cohort is from a population-based surveillance program, the 283 collected and sequenced isolates represent a convenience sample which may limit 284 generalizability and our sample size was not powered to detect clinical outcomes.

285

In conclusion, *mcr-9* may not have actionable public health implications as other *mcr*alleles, most of which consistently display colistin resistance. However, given the
increased AMR and HMR gene content, continued genomic surveillance of multidrugresistant organisms to monitor for the emergence of AMR genes such as *mcr-9* is

- 290 prudent. Especially as changes in the up or downstream genetic context or the
- accumulation of mutations may impact its ability to confer colistin resistance.
- 292
- 293 Methods
- 294

CRE cases were identified by routine queries on automated testing instruments in the
clinical labs that serve residents of the GA EIP catchment area. Clinical characteristics
were obtained through medical record review, all-cause mortality data was obtained
through the Georgia Vital Statistics records, and hospital readmission data was
obtained through the Department of Public Health's hospital discharge datasets.
Georgia EIP surveillance activities are reviewed and approved by the Emory University
Institutional Review Board.

302

303 From 2012-2015, a CRE case was defined as an isolate of E. coli, E. cloacae 304 complex, K. (formally Enterobacter) aerogenes, K. pneumoniae, or K. oxytoca collected 305 from a normally sterile body site (e.g., bloodstream) or urine that tested non-susceptible to ≥1 carbapenem (imipenem, meropenem, or doripenem) and resistant to all 3rd 306 generation cephalosporins tested (ceftriaxone, ceftazidime, and cefotaxime) by testing 307 performed at the local collection microbiology laboratory. Beginning in 2016, the 308 309 phenotypic case definition was changed to resistance to ≥ 1 carbapenem (now including 310 ertapenem) with no cephalosporin parameter. Antibiotic susceptibility interpretations 311 were determined using the current Clinical and Laboratory Standards Institute 312 breakpoints (31). Fluoroquinolone resistance was defined as non-susceptibility

313 (intermediate or resistant) to \geq 1 fluoroquinolone. DTR was defined as intermediate or 314 resistant to all reported agents in carbapenem, β -lactam, and fluoroquinolone categories 315 (14, 15).

316

An incident CRE case was defined as the first CRE isolate from a patient during a 30-

318 day period that met the surveillance definition. All incident CRE cases underwent

319 medical record review using a standardized abstraction form. Both inpatient and

320 outpatient medical records were reviewed for patient demographics, underlying clinical

321 comorbidities, location of culture collection, specimen source, associated infectious

322 syndromes, relevant health care exposures and patient outcomes. 90-day mortality was

323 determined based by matching to vital records.

324

A convenience sample of CRE isolates are collected annually and submitted to the CDC for further characterization. Isolates that are collected and matched to an incident case with a completed case report form are eligible for shipment. All isolates undergo repeat reference BMD at the CDC followed by whole genome sequencing using an Illumina MiSeq benchtop sequencer.

330

All *mcr-9* positive and a comparative control group of *mcr-9* negative *E. cloacae*complex isolates underwent additional population analysis profiling and inducible
resistance testing at the Emory Investigational Clinical Microbiology Core as previously
described (20). Briefly, all isolates were tested via the population analysis profile (PAP)
method. This consists of plating overnight cultures of each isolate onto solid Muller-

336 Hinton (MH) agar with or without colistin concentrations of 0.5, 1, 2, 4, 16, 32, and 100 337 µg/ml. Surviving colonies were enumerated and used to detect colistin-resistant 338 subpopulations characteristic of heteroresistance (20). Inducible resistance testing was 339 performed as previously described (32). Briefly, a single colony of each clinical isolate was grown in Muller-Hinton (MH) broth overnight at 37°C, and cultures were diluted 340 341 1:100 in MH broth containing serially increasing concentrations of colistin, starting at the one-half MIC value of the respective isolate, and doubling every 24 hours until bacterial 342 growth was completely inhibited (with no bacteria growth after spreading 100 µL of the 343 344 culture on MH agar plates supplemented with corresponding concentration of colistin). The concentration of colistin at which bacterial growth was completely inhibited was 345 346 recorded as the final colistin concentration. 347

Bioinformatic Methods 348

349

350 Fastg files of Enterobacter cloacae complex isolates of interest were downloaded from 351 the Sequence Read Archive (SRA) repository maintained by the National Center for 352 Biotechnology Information (NCBI) using the fasterg-dump tool from the SRA Toolkit V. 2.5.7 (http://ncbi.github.io/sra-tools/). Illumina reads were quality filtered using 353 354 Trimmomatic (33) and assembled *de novo* using SPAdes v3.13 (34). Pairwise 355 comparisons of average nucleotide identity on the assembled genomes were performed 356 with the Mashmap method using fastANI v1.32 (35). Gene sequences were predicted 357 with Prodigal v2.6.3 (36) and annotated with Prokka v1.14.6 (37). Antimicrobial 358 resistance and virulence gene content was assessed using AMRFinder Plus (38).

359	Presence of plasmids and point mutations in housekeeping genes associated with
360	colistin resistance were assessed using the ResFinder and PlasmidFinder web interface
361	with default settings and the E. coli database (39, 40). AMR gene presence/absence
362	heatmaps were created using the package pheatmap on R version 4.0.2 (Vienna,
363	Austria) and the RStudio interface version 1.3.1073 (Boston, MA, USA). Core genes
364	were defined using Roary v3.13 (41). A phylogenetic tree based on a core gene
365	alignment containing 1942 genes was generated using IQtree v2.0.3 (42). A maximum
366	likelihood tree was generated by running 1,000 bootstrap replicates under the
367	generalized time-reversible model of evolution. The tree was visualized and annotated
368	using Interactive Tree of Life (iTOL) v4 (43). Pan-genome wide comparison of core
369	genomes of mcr-9 positive to mcr-9 negative genomes was completed using scoary
370	(44).

371

372 Statistical analysis

373

Annual incidence rates for CRE cases were calculated using the annual US census estimates of the surveillance area population as the denominator. Descriptive analyses were performed to summarize specimen information, health care exposures, outcomes, and microbiological results of incident cases; χ^2 and Wilcoxon rank sum tests were used to compare groups when applicable. Gene differences were assessed by a *p*value adjusted with Bonferroni's method for multiple comparisons correction. Statistical analysis was performed using R version 4.0.2 (Vienna, Austria) and the RStudio

- interface version 1.3.1073 (Boston, MA, USA). A 2-sided P value of <.05 was
- 382 considered statistically significant.
- 383
- 384 Funding
- 385
- 386 EIP Surveillance of the Multi-site Gram-Negative Surveillance Initiative (MuGSI) was
- funded through the Centers for Disease Control and Prevention's Emerging Infections
- 388 Program [U50CK000485].
- 389
- 390

391 Acknowledgments

392

393 We would like to thank the EIP and MuGSI staff and the CDC laboratory staff for their

dedication and work to collect, validate, clean, and maintain the data used in this

analysis. We would like to thank Alison Laufer Halpin for supervising the sequencing

396 efforts of these isolates.

397

Table 1: Carbapenem-resistant *E. cloacae* complex clinical and microbiological

400 characteristics

	All (N=27)	<i>mcr-9</i> positive	<i>mcr-9</i> negative *	<i>p</i> value
	n (%)	(N=13)	(N=14)	
		n (%)	n (%)	
Culture Source				0.33
Urine	24 (88.9)	12 (92.3)	12 (85.7)	
Blood	2 (7.4)	1 (7.7)	1 (7.1)	
Peritoneal Fluid	1 (3.7)	0 (0.0)	1 (7.1)	
Year				0.62
2012	1 (3.7)	1 (7.7)	0 (0.0)	
2013	8 (29.6)	2 (15.4)	6 (42.9)	
2014	2 (7.4)	1 (7.7)	1 (7.1)	
2015	3 (11.1)	3 (23.1)	0 (0.0)	
2016	9 (33.3)	4 (30.8)	5 (35.7)	
2017	4 (14.9)	2 (15.4)	2 (14.3)	
Infection Onset				0.71
Hospital Onset	3 (11.1)	2 (15.4)	1 (7.1)	
Healthcare Associated-	10 (37.0)	4 (30.8)	6 (42.9)	
Community Onset				
Long Term Care Facility Onset	14 (51.9)	7 (53.8)	7 (50.0)	
Microbiology Characteristics				

Colistin MIC (median[range])**	0.5 [<0.25 -	0.5 [<0.25 -1.00]	0.5 [<0.25 ->8.0]	0.11
	>0.8]			
Resistant	3 (11.1)	0	3 (21.4)	0.25
Heteroresistant	13 (48.1)	5 (38.5)	8 (57.1)	0.56
Inducible resistance	4 (14.8)	2 (15.4)	2 (14.3)	1.00
Difficult-to-Treat Resistance	13 (48.1)	8 (61.5)	5 (35.7)	0.34
Outcomes				
Hospitalization within 29 days	10 (37.0)	5 (38.5)	5 (35.7)	0.86
after culture				
ICU admission ***^	4 (40.0)	2 (40.0)	2 (40.0)	1.00
In-hospital mortality ^	1 (10.0)	1 (20.0)	0 (0.0)	0.59
90-day Mortality	5 (18.5)	4 (30.8)	1 (7.1)	0.28

402

403 *1 mcr-10 positive isolate

404 ** MIC units : μg/mL

405 *** Any ICU admission 7 days prior or 6 days after specimen collection

406 ^ among 10 hospitalized patients, 5 in each group (*mcr-9* positive and negative)

408 Table 2. Highest ranking genes for association with *mcr-9* presence

Gene*	Comment	Odds Ratio	Bonferroni
			adjusted <i>p</i> -
			value
smc	Chromosome partition protein Smc	00	1.60E-06
dcm2	DNA-cytosine methyltransferase	∞	1.60E-06
pcoE2	putative copper-binding protein PcoE	∞	2.88E-05
hns2	DNA-binding protein H-NS, plasmid	∞	3.36E-05
group_10390	Tn3 family transposase ISEc63	00	3.36E-05
hipA	Serine/threonine-protein kinase toxin HipA	∞	3.36E-05
rcnR2	Transcriptional repressor RcnR	∞	0.00030219
hha2	Hemolysin expression-modulating protein Hha	∞	0.00036934
uvrD2	DNA helicase II	∞	0.00036934
parM	Plasmid segregation protein	∞	0.00036934
higB-1	Toxin HigB-1	∞	0.00036934
group_1846	Tn3 family transposase ISEc63	∞	0.00036934
dam2	DNA adenine methylase	∞	0.00036934
repB	RepFIB replication protein A	∞	0.00036934
traC	Protein TraC	∞	0.00036934
group_7173	Stable plasmid inheritance protein	∞	0.00036934
yjcD	Putative ATP-dependent DNA helicase YjcD	304	0.00054522
umuD2	Protein UmuD	00	0.00283164

dsbC_2	Thiol:disulfide interchange protein DsbC	00	0.00283164
virB	Virulence regulon transcriptional activator VirB	∞	0.00283164
umuC_3	Protein UmuC	00	0.00283164
group_7174	IS110 family transposase ISEsa2	142.5	0.00540586
merA	Mercuric reductase	00	0.01698985
fieF_2	Ferrous-iron efflux pump FieF	90.7	0.03283809
arsB_2	Arsenical pump membrane protein	67.5	0.04368339
group_7063	ISNCY family transposase ISEsa1	67.5	0.04368339
group_8953	ISNCY family transposase ISBcen27	67.5	0.04368339
arsH	NADPH-dependent FMN reductase ArsH	67.5	0.04368339
arsC2	Arsenate reductase	67.5	0.04368339
410			
411 hypot	hetical proteins not included		
412			
413			

...-

414

415

417 Figure 1.





Figure Legend 1. Carbapenem-resistant Enterobacterales (CRE) count (A) and crude
annual incidence per 100,000 population (B) by species across from the Georgia
Emerging Infections program from 2012 to 2017. Beginning in 2016, the phenotypic
CRE case definition was changed to resistance to ≥1 carbapenem (now including
ertapenem) with no cephalosporin parameter.





442

443 Figure Legend 2: Phylogeny (A) and average nucleotide identity heatmap (B) of mcr-9 positive (n=13) and mcr-9 negative (n=14) E. cloacae complex genomes from Georgia 444 Emerging Infection program in addition to 9 available *E. cloacae* complex genomes 445 (three mcr-9 positive, six mcr-9 negative) from the National Institutes of Health. A 446 phylogenetic tree based on a core gene alignment containing 1,904 genes defined 447 using Roary v3.13.0. was generated using IQtree v2.0.3. A maximum likelihood tree 448 was generated by running 1,000 bootstrap replicates under the generalized time-449 450 reversible model of evolution. The tree was visualized and annotated using Interactive Tree of Life (iTOL) v4. Pairwise comparisons of average nucleotide identity on the 451 assembled genomes were performed with the Mashmap method using fastANI v1.32. 452 453

454 Abbreviations: GA EIP: Georgia Emerging Infections Program, NIH: National Institutes

455 of Health,

457 Figure 3





- 464 AMRFinder Antimicrobial resistance gene presence/absence heatmaps were
- 465 created using the package pheatmap on R version 4.0.2 (Vienna, Austria) and the
- 466 RStudio interface version 1.3.1073 (Boston, MA, USA).

467 **References**

468

- 469 1. Babiker A, Clarke LG, Saul M, Gealey JA, Clancy CJ, Nguyen MH, Shields RK. 2020.
- 470 Changing epidemiology and decreased mortality associated with Carbapenem-resistant
- 471 Gram-negative bacteria from 2000 2017. Clin Infect Dis doi:10.1093/cid/ciaa1464.
- 472 2. Babiker A, Evans DR, Griffith MP, McElheny CL, Hassan M, Clarke LG, Mettus RT,
- 473 Harrison LH, Doi Y, Shields RK, Van Tyne D. 2020. Clinical and Genomic Epidemiology
- 474 of Carbapenem-Nonsusceptible *Citrobacter* spp. at a Tertiary Health Care Center over 2
- 475 Decades. Journal of Clinical Microbiology 58:e00275-20.
- 476 3. World Health Organization. 2019. Critically important antimicrobials for human
- 477 medicine, 6th revision

478 . www.who.int/foodsafety/publications/antimicrobials-sixth/en/. Accessed 7th May 2021.

- 479 4. Eljaaly K, Bidell MR, Gandhi RG, Alshehri S, Enani MA, Al-Jedai A, Lee TC. 2021.
- 480 Colistin Nephrotoxicity: Meta-analysis of Randomized Controlled Trials. Open Forum
 481 Infectious Diseases doi:10.1093/ofid/ofab026.
- 482 5. Strich JR, Ricotta E, Warner S, Lai YL, Demirkale CY, Hohmann SF, Rhee C, Klompas
- 483 M, Palmore T, Powers JH, Dekker JP, Adjemian J, Matsouaka R, Woods CW, Danner
- 484 RL, Kadri SS. 2021. Pharmacoepidemiology of Ceftazidime-Avibactam Use: A
- 485 Retrospective Cohort Analysis of 210 US Hospitals. Clin Infect Dis 72:611-621.
- 486 6. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang
- 487 X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016.
- 488 Emergence of plasmid-mediated colistin resistance mechanism *mcr-1* in animals and
- 489 human beings in China: a microbiological and molecular biological study. Lancet Infect
- 490 Dis 16:161-8.

491	7.	Ling Z, Yin W, Shen Z, Wang Y, Shen J, Walsh TR. 2020. Epidemiology of mobile
492		colistin resistance genes mcr-1 to mcr-9. Journal of Antimicrobial Chemotherapy
493		75:3087-3095.
494	8.	Carroll LM, Gaballa A, Guldimann C, Sullivan G, Henderson LO, Wiedmann M. 2019.
495		Identification of Novel Mobilized Colistin Resistance Gene mcr-9 in a Multidrug-
496		Resistant, Colistin-Susceptible Salmonella enterica Serotype Typhimurium Isolate. mBio
497		10:e00853-19.
498	9.	Li Y, Dai X, Zeng J, Gao Y, Zhang Z, Zhang L. 2020. Characterization of the global
499		distribution and diversified plasmid reservoirs of the colistin resistance gene mcr-9.
500		Scientific Reports 10:8113.
501	10.	Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M,
502		Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM,
503		Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford
504		N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella
505		pneumoniae carbapenemases. Lancet Infect Dis 13:785-96.
506	11.	Wilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ, Bonomo RA, Perez F.
507		2017. Carbapenem-Resistant Enterobacter cloacae in Patients from the US Veterans
508		Health Administration, 2006-2015. Emerg Infect Dis 23:878-880.
509	12.	Annavajhala MK, Gomez-Simmonds A, Uhlemann AC. 2019. Multidrug-Resistant
510		Enterobacter cloacae Complex Emerging as a Global, Diversifying Threat. Front
511		Microbiol 10:44.
512	13.	Chea N, Bulens SN, Kongphet-Tran T, Lynfield R, Shaw KM, Vagnone PS, Kainer MA,
513		Muleta DB, Wilson L, Vaeth E, Dumyati G, Concannon C, Phipps EC, Culbreath K,
514		Janelle SJ, Bamberg WM, Guh AY, Limbago B, Kallen AJ. 2015. Improved Phenotype-
515		Based Definition for Identifying Carbapenemase Producers among Carbapenem-
516		Resistant Enterobacteriaceae. Emerging infectious diseases 21:1611-1616.

517	14.	Kadri SS, Lai YL, Ricotta EE, Strich JR, Babiker A, Rhee C, Klompas M, Dekker JP,
518		Powers JH, III, Danner RL, Adjemian J, Initiative NAROR. 2019. External Validation of
519		Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative
520		Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals.
521		Open Forum Infectious Diseases 6.
522	15.	Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee
523		C, Klompas M, Dekker JP, Powers JH, 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner
524		RL. 2018. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US
525		Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of
526		Resistance to All First-line Agents. Clin Infect Dis 67:1803-1814.
527	16.	Weingarten RA, Johnson RC, Conlan S, Ramsburg AM, Dekker JP, Lau AF, Khil P,
528		Odom RT, Deming C, Park M, Thomas PJ, Henderson DK, Palmore TN, Segre JA,
529		Frank KM. 2018. Genomic Analysis of Hospital Plumbing Reveals Diverse Reservoir of
530		Bacterial Plasmids Conferring Carbapenem Resistance. mBio 9.
531	17.	Kieffer N, Royer G, Decousser J-W, Bourrel A-S, Palmieri M, Ortiz De La Rosa J-M,
532		Jacquier H, Denamur E, Nordmann P, Poirel L. 2019. mcr-9 an Inducible Gene Encoding

- 533 an Acquired Phosphoethanolamine Transferase in *Escherichia coli*, and Its Origin.
- 534 Antimicrobial Agents and Chemotherapy 63:e00965-19.
- 535 18. Breland EJ, Zhang EW, Bermudez T, Martinez CR, 3rd, Hadjifrangiskou M. 2017. The
 536 Histidine Residue of QseC Is Required for Canonical Signaling between QseB and PmrB
 537 in Uropathogenic Escherichia coli. J Bacteriol 199.
- 538 19. Tyson GH, Li C, Hsu C-H, Ayers S, Borenstein S, Mukherjee S, Tran T-T, McDermott
- 539 PF, Zhao S. 2020. The mcr-9 Gene of Salmonella and Escherichia coli is Not Associated
- 540 with Colistin Resistance in the United States. Antimicrobial Agents and Chemotherapy
- 541 64:e00573-20.

542	20.	Nicoloff H, Hjort K, Levin BR, Andersson DI. 2019. The high prevalence of antibiotic
543		heteroresistance in pathogenic bacteria is mainly caused by gene amplification. Nat
544		Microbiol 4:504-514.
545	21.	Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS, Hunstad DA, Hultgren
546		SJ. 2018. Carbapenem-Resistant Klebsiella pneumoniae Exhibiting Clinically
547		Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of
548		Infection. mBio 9:e02448-17.
549	22.	Band VI, Satola SW, Smith RD, Hufnagel DA, Bower C, Conley AB, Rishishwar L, Dale
550		SE, Hardy DJ, Vargas RL, Dumyati G, Kainer MA, Phipps EC, Pierce R, Wilson LE,
551		Sorensen M, Nilsson E, Jordan IK, Burd EM, Farley MM, Jacob JT, Ernst RK, Weiss DS.
552		2021. Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant
553		Enterobacterales in the United States. mBio 12:e02881-20.
554	23.	Centers for Disease Control. 2019. Antibiotic resistance threats in the United States,
555		2019.
556	24.	Germain E, Castro-Roa D, Zenkin N, Gerdes K. 2013. Molecular mechanism of bacterial
557		persistence by <i>HipA</i> . Mol Cell 52:248-54.
558	25.	Nguyen CC, Hugie CN, Kile ML, Navab-Daneshmand T. 2019. Association between
559		heavy metals and antibiotic-resistant human pathogens in environmental reservoirs: A
560		review. Frontiers of Environmental Science & Engineering 13:46.
561	26.	Kizny Gordon AE, Mathers AJ, Cheong EYL, Gottlieb T, Kotay S, Walker AS, Peto TEA,
562		Crook DW, Stoesser N. 2017. The Hospital Water Environment as a Reservoir for
563		Carbapenem-Resistant Organisms Causing Hospital-Acquired Infections—A Systematic
564		Review of the Literature. Clinical Infectious Diseases 64:1435-1444.
565	27.	Kamathewatta K, Bushell R, Rafa F, Browning G, Billman-Jacobe H, Marenda M. 2020.
566		Colonization of a hand washing sink in a veterinary hospital by an Enterobacter

567	hormaechei strain	carrying	a multiple	resistances to	o high in	nportance	antimicrobials.

- 568 Antimicrobial Resistance & Infection Control 9:163.
- 569 28. Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, McCarthy N,
- 570 Paul P, McDonald LC, Kallen A, Fiore A, Craig M, Baggs J. 2020. Multidrug-Resistant
- 571 Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med 382:1309-
- 572 1319.
- 573 29. Chen HD, Groisman EA. 2013. The biology of the PmrA/PmrB two-component system:
- 574 the major regulator of lipopolysaccharide modifications. Annu Rev Microbiol 67:83-112.
- 575 30. Gwozdzinski K, Azarderakhsh S, Imirzalioglu C, Falgenhauer L, Chakraborty T. 2018.
- 576 An Improved Medium for Colistin Susceptibility Testing. Journal of Clinical Microbiology 577 56:e01950-17.
- 578 31. Clinical and Laboratory Standards Institute. 2021. Performance standards for
 579 antimicrobial susceptibility testing, 31st informational supplement.
- 580 32. Luo Q, Niu T, Wang Y, Yin J, Wan F, Yao M, Lu H, Xiao Y, Li L. 2019. In vitro reduction
- 581 of colistin susceptibility and comparative genomics reveals multiple differences between
- 582 MCR-positive and MCR-negative colistin-resistant Escherichia coli. Infection and drug
- 583 resistance 12:1665-1674.
- 33. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina
 sequence data. Bioinformatics 30:2114-20.
- 58634.Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. 2020. Using SPAdes
- 587 De Novo Assembler. Current Protocols in Bioinformatics 70:e102.
- 588 35. Jain C, Rodriguez-R LM, Phillippy AM, Konstantinidis KT, Aluru S. 2018. High
- 589 throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries.
- 590 Nature Communications 9:5114.

591	36.	Hyatt D, Chen GL, Locascio PF, Land ML, Larimer FW, Hauser LJ. 2010. Prodigal:
592		prokaryotic gene recognition and translation initiation site identification. BMC
593		Bioinformatics 11:119.
594	37.	Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics
595		30:2068-9.
596	38.	Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH,
597		Hoffmann M, Pettengill JB, Prasad AB, Tillman GE, Tyson GH, Klimke W. 2021.
598		AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic
599		links among antimicrobial resistance, stress response, and virulence. Sci Rep 11:12728.
600	39.	Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. 2017.
601		PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance
602		associated with chromosomal point mutations in bacterial pathogens. J Antimicrob
603		Chemother 72:2764-2768.
604	40.	Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller
605		Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using
606		PlasmidFinder and plasmid multilocus sequence typing. Antimicrobial agents and
607		chemotherapy 58:3895-3903.
608	41.	Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, Fookes M, Falush
609		D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis.
610		Bioinformatics (Oxford, England) 31:3691-3693.
611	42.	Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. 2017.
612		ModelFinder: fast model selection for accurate phylogenetic estimates. Nature Methods
613		14:587-589.
614	43.	Letunic I, Bork P. 2021. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic
615		tree display and annotation. Nucleic Acids Research doi:10.1093/nar/gkab301.

- 616 44. Brynildsrud O, Bohlin J, Scheffer L, Eldholm V. 2016. Rapid scoring of genes in
- 617 microbial pan-genome-wide association studies with Scoary. Genome Biol 17:238.

619 Supplementary Material

- 620 **Supplemental Table 1:** Definitions of carbapenem-resistant Enterobacterales
- 621 (CRE) and difficult-to-treat resistance (DTR) used during the study period.

622

Definition	Period	Species	Susceptibility Phenotype
Initial GA EIP	2011–2015	Escherichia coli	Intermediate or resistant to:
surveillance		Klebsiella pneumoniae	- Imipenem (MIC ≥2 μg/mL), or
definition		Klebsiella oxytoca	- Meropenem (MIC ≥2 μg/mL), or
		Enterobacter cloacae	- Doripenem (MIC ≥2 μg/mL)
		complex	
		Klebsiella aerogenes ^a	AND resistant to ^b :
			- Ceftazidime (MIC ≥16 μg/mL), and
			- Ceftriaxone (MIC ≥4 μg/mL), and
			- Cefotaxime (MIC ≥4 μg/mL)
Revised GA	2016–	Escherichia coli	Resistant to:
EIP	present	Klebsiella pneumoniae	- Imipenem (MIC ≥4 μg/mL), or
surveillance		Klebsiella oxytoca	- Meropenem (MIC ≥4 μg/mL), or
definition		Enterobacter cloacae	- Doripenem (MIC ≥4 μg/mL), or
		complex	
		Klebsiella aerogenes ^a	- Ertapenem (MIC ≥2 μg/mL)

DTR	2011–2017	Enterobacter cloacae	Intermediate or resistant to all tested
		complex	and reported agents in carbapenem,
			β -lactam, and fluoroquinolone
			categories

624

- 625 a. Formerly *Enterobacter aerogenes*
- 626 b. If the antibiotics were tested

627

- 628 Abbreviations: GA EIP: Georgia Emerging Infections Program; DTR: difficult-to-treat
- 629 resistance; MIC: minimum inhibitory concentrations



633 Supplementary Table 2: Antimicrobial Susceptibility testing of Carbapenem-

634 resistant *E. cloacae* complex by *mcr-9* status

635

Antibiotic	Median (range) MIC*	Suscep	tible N (%)	Intermed	liate N (%)**	Resist	ant N (%)	P value
	mcr-9 positive	mcr-9 negative	mcr-9	mcr-9	mcr-9	mcr-9	mcr-9	mcr-9	***
	(n=13)	(n=14)	positive	negative	positive	negative	positive	negative	
			(n=13)	(n=14)	(n=13)	(n=14)	(n=13)	(n=14)	
Aminoglycosides									
Amikacin	≤1 (≤1->64)	≤1 (≤1-16)	12 (92.3)	14 (100)	0 (0)	0 (0)	1 (7.7)	0 (0)	0.97
Gentamicin	8 (≤0.25->16)	0.37 (≤0.25->16)	4 (30.8)	11 (78.6)	3 (23.1)	1 (7.1)	6 (46.2)	2 (14.3)	0.04
Tobramycin	8 (≤0.5->16)	≤0.5 (≤0.5 ->16)	3 (23.1)	9 (64.3)	4 (30.8)	2 (14.3)	6 (46.2)	3 (21.4)	0.10
B-lactams									
Aztreonam	>64 (64->64)	>64 (32->64)	0 (0)	0 (0)	0 (0)	0 (0)	13 (100)	14 (100)	n/a
Ceftriaxone	>32 (16->32)	>32 (32->32)	0 (0)	0 (0)	0 (0)	0 (0)	13 (100)	14 (100)	n/a
Ceftazidime	>128 (64->128)	>128 (64->128)	0 (0)	0 (0)	0 (0)	0 (0)	13 (100)	14 (100)	n/a
Cefepime	>32 (1->32)	16 (≤0.5 ->32)	1 (7.7)	5 (35.7)	1 (7.7)	1 (7.1)	11 (84.6)	8 (57.1)	0.21
Ertapenem	8 (≤0.12->8)	4 (0.25->8)	2 (15.4)	3 (21.4)	0 (0)	0 (0)	11 (84.6)	11 (78.6)	1.00
Doripenem	2 (≤0.12-8)	1 (≤0.12-8)	5 (38.5)	8 (57.1)	3 (23.1)	2 (14.3)	5 (38.5)	4 (28.6)	0.61
Imipenem	2 (≤0.5-8)	1 (≤0.5->64)	5 (38.5)	7 (50.0)	2 (15.4)	1 (7.1)	6 (46.2)	6 (42.9)	0.73
Piperacillin-Tazobactam	>128 (16->128)	>128 (≤4->128)	1 (7.7)	1 (7.1)	1 (7.7)	0 (0)	11 (84.6)	13 (92.9)	0.57
Meropenem	2 (≤0.12->8)	0.5 (≤0.12->8)	5 (38.5)	8 (57.1)	4 (30.8)	0 (0)	4 (30.8)	6 (42.9)	0.08
Fluoroquinolones									
Ciprofloxacin	>8 (0.5->8)	3 (≤0.25->8)	0 (0)	6 (42.9)	1 (7.7)	0 (0)	12 (92.3)	8 (57.1)	0.02
Levofloxacin	>8 (0.1->8)	3 (≤0.12->8)	0 (0)	6 (42.9)	1 (7.7)	0 (0)	12 (92.3)	8 (57.1)	0.02
Tetracyclines									
Tetracycline	16 (≤2.0->32)	4 (≤2-32)	5 (38.5)	9 (64.3)	1 (7.7)	1 (7.1)	7 (53.8)	4 (28.6)	0.38
Tigecycline	1 (≤0.5->4)	0.76 (≤0.5->4)	11 (84.6)	9 (64.3)	1 (7.7)	4 (28.6)	1 (7.7)	1 (7.1)	0.37
Miscellaneous									
Trimethoprim-	>8 (1->8)	(≤0.5 (≤0.5->8)	2 (15.4)	12 (85.7)	0 (0)	0 (0)	11 (84.6)	2 (14.3)	0.001

Sulfamethoxazole

637	
638	* MICs in μg/mL
639	** Intermediate is equivalent to the category susceptible dose dependent for cefepime
640	*** Calculated for proportion mcr-9 positive categorized as S/I/R compared to mcr-9
641	negative isolates.
642	
643	Abbreviation: MIC: minimum inhibitory concentration
644	
645	

646				
647				
648 Supp	lementary Table 3	: Plasmid con	tents of Carbapenem-res	sistant <i>E. cloaca</i> e
649 com r	plex genomes by n	ncr-9 status		
650				
Isolate	Plasmid	Identity (%)	Plasmid Accession	
mcr-9 positive				
	ColRNAI	100	DQ298019	
SRR103771/7	IncFIA(HI1)	98.0	AF250878	
511110577147	IncHI2A	100	BX664015	
	pKPC-CAV1193	98.7	CP013325	
SRR3467253	IncHI2A	100	BX664015	
	IncHI2A	99.5	BX664015	
SRR4035127	IncFII(pECLA)	96.8	CP001919	
	IncFIB(pECLA)	99.5	CP001919	
SRR4035132	IncHI2A	100	BX664015	
••••••••	IncR	100	DQ449578	
	Col440I	83.2	CP023920	
SRR5666570	IncFII(pECLA)	96.1	CP001919	
	IncHI2A	100	BX664015	
	pKPC-CAV1193	98.7	CP013325	
SRR5666425	IncHI2A		BX664015	
	IncFIA(HI1)	98.0	AF250878	
SRR5666426	IncHI2A	100	BX664015	
	pKPC-CAV1193	98.7	CP013325	
SRR5666432	IncFIB(pB171)	91.2	AB024946	

_

	IncFII(SARC14)	94.8	JQ418540
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
	Col440I	83.2	CP023920
SRR10377089	Col440II	84.6	CP023921
	IncHI2A	100	BX664015
	IncX5	99.7	MF062700
	IncFIA(HI1)	98.0	AF250878
	IncFIB(pECLA)	100	CP001919
SRR10377142			
	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
	Col440II	83.9	CP023921
SRR10377154	IncFIB(pECLA)	100	CP001919
	IncFII(pECLA)	100	CP001919
	IncFIA(HI1)	98.0	AF250878
	IncFIB(pECLA)	100	CP001919
SRR12902635	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
	IncFIA(HI1)	97.8	AF250878
	IncFIB(pECLA)	100	CP001919
SRR12902473	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
	pKPC-CAV1193	98.7	CP013325
SRR6674815	Col440II	84.3	CP023921
	IncFIB(pECLA)	100	CP001919

	IncFII(pECLA)	99.6	CP001919
	IncHI2A	100	BX664015
	IncN	99.6	AY046276
	IncR	100	DQ449578
	Col(pHAD28)		
	Col440II	90.8	CP023921
	IncFIB(K)	84.8	JN233704
SRR6674819	IncFII(pECLA)	99.5	CP001919
	IncHI2A	100	BX664015
	IncQ2	94.2	FJ696404
	IncR	100	DQ449578
SRR6674864	IncHI2A	100	BX664015
	pKPC-CAV1193	100	CP013325
mcr-9 negative			
SRR3996257	Col440II	84.4	CP023921
	IncX3	100	JN247852
SRR4035128	n/a		
SRR4035129	Col440II	84.6	
	pKPC-CAV1193	100	CP013325
SRR4035130	n/a		
SRR4035131	n/a		
SRR12902528	Col440II	84.4	CP023921
	IncFII(pECLA)	99.9	CP001919
	IncFIB(pECLA)	100	CP001919
SRR5666492	IncFIB(pENTE01)	81.1	CP000654
	IncFII(pECLA)	100	CP001919
	IncHI1A(NDM-CIT)	100	JX182975

	IncHI1B(pNDM-CIT)	99.1	JX182975
	Col440II	84.4	CP023921
	IncFIB(pB171)	91.2	AB024946
SRR10377150	IncFIB(pHCM2)	97.5	AL513384
	IncFII(SARC14)	94.8	JQ418540
	pKPC-CAV1193	98.7	CP013325
SRR10377039	IncX5	100	
	pKPC-CAV1193	100	CP013325
	IncFIA(HI1)	97.8	AF250878
SRR10377142	IncFIB(pECLA)	100	CP001919
•••••••	IncFII(pECLA)	100	CP001919
	IncHI2A	100	BX664015
SRR10377155	IncFII(pECLA)	97.5	
	IncR	94.0	
SRR12902580	IncFIB(pECLA)	100	CP001919
•••••••••••	IncFII(pECLA)	100	CP001919
SRR12902479	IncFIB(pECLA)	100	CP001919
	IncFII(pECLA)	100	CP001919
SRR12902477	IncFIB(pHCM2)	97.3	AL513384
	IncFIB(pQil)	100	JN233705
SRR3996257	IncX3	100	JN247852
SRR6674810	IncN	99.8	AY046276
	IncFIB(pECLA)	100	CP001919
	IncFIB(pENTE01)	80.7	CP000654
SRR6674817	IncFIB(pQil)	100	JN233705
	IncFII(pECLA)	97.9	CP001919
	IncQ2	81.1	FJ696404

	pKPC-CAV1193	100	CP013325
	IncFIB(pECLA)	100	CP001919
	IncFIB(pENTE01)	80.7	CP000654
SRR6674821	IncFIB(pQil)	100	JN233705
	IncFII(pECLA)	99.9	CP001919
	IncQ2	81.1	FJ696404
	pKPC-CAV1193	100	CP013325
SRR6674823	IncFIB(pENTAS01)	93.2	CP003027
	IncFII(SARC14)	99.5	JQ418540
	Col440II	84.0	CP023921
	IncFIB(pECLA)	100	CP001919
SRR6674824	IncFII(pECLA)	99.6	CP001919
	IncN	99.8	AY046276
	IncR	100	DQ449578
SRR6674865	IncN	99.8	AY046276
651			

653 Supplementary Figures

654 Supplementary Figure 1



- 664
- 665 **Supplementary Figure 1 legend:** Waffle-plot of Carbapenem-resistant
- 666 Enterobacterales cases by species collected by Georgia Emerging Infections Program
- 667 between 2012-2017.

669 Supplementary Figure 2

670



671



- 680 was visualized and Facility IDs and year of isolation were annotated using Interactive
- Tree of Life (iTOL) v4. for GA EIP *mcr-9* positive genomes only.
- 682
- 683 Abbreviations: GA EIP: Georgia Emerging Infections Program, NIH: National Institutes
- 684 of Health
- 685

686

687 **Supplementary Figure 3**

688



691 Supplementary Figure 3 Legend: Genomes were annotated using Prodigal and

virulence gene content was assessed using AMRFinder. Virulence gene 692

- 693 presence/absence heatmaps were created using the package pheatmap on R version
- 4.0.2 (Vienna, Austria) and the RStudio interface version 1.3.1073 (Boston, MA, USA).